How to become investor ready: a guide for early-stage biotechs
![investor-ready](https://boydconsultants.com/wp-content/uploads/2024/07/Website-news-cover-image-size-1.png)
For many early-stage and start-up biotech companies, a key consideration is how to prepare to be investor ready, to raise the funding required to progress product development programs.
Part 3: Navigating an FDA meeting – best practices for maximizing your time and effort
![FDA meeting](https://boydconsultants.com/wp-content/uploads/2024/06/Website-news-cover-image-size-91.png)
In this three-part blog series, Dr Eric Hardter, Associate Director of Regulatory Affairs at Boyds, provides advice and guidance for sponsors on conducting FDA meetings and discusses ways of ensuring a productive outcome.
Part 2: Navigating an FDA meeting – best practices for maximizing your time and effort
![FDA meeting](https://boydconsultants.com/wp-content/uploads/2024/05/Website-news-cover-image-size-91-1.png)
In this three-part blog series, Dr Eric Hardter, Associate Director of Regulatory Affairs at Boyds, provides advice and guidance to sponsors on conducting FDA meetings and discusses ways of ensuring a productive outcome.
A reflection on the EU Clinical Trials Regulation and future prospects
![clinical trial regulation](https://boydconsultants.com/wp-content/uploads/2024/06/Website-news-cover-image-size-92.png)
The field of clinical trials within the European Union (EU) has undergone a significant transformation in recent years driven by implementation of the new Clinical Trials Regulation (EU No 536/2014) (CTR) aimed at harmonisation of the rules across the EU for conducting clinical trials, enhancing patient safety, data transparency and overall trial efficiency.
Part 1: Navigating an FDA meeting – best practices for maximizing your time and effort
![FDA meetings](https://boydconsultants.com/wp-content/uploads/2024/05/Website-news-cover-image-size-91.png)
In this three-part blog series, Dr Eric Hardter, Associate Director of Regulatory Affairs at Boyds, provides advice and guidance to sponsors on conducting FDA meetings and discusses ways of ensuring a productive outcome.
National DNA Day: Gene Therapy – The future has arrived.
![National DNA Day](https://boydconsultants.com/wp-content/uploads/2024/04/Copy-of-Website-news-cover-image-size-3-1024x768.png)
National DNA Day focuses on the successful completion of the Human Genome Project back in 2003, as well as the discovery of DNA’s double helix in 1953.
The latest trends in US drug development
![US drug development](https://boydconsultants.com/wp-content/uploads/2024/03/Website-news-cover-image-size-83.png)
In this blog, Katy Rudnick, Vice President and Head of US Regulatory Affairs at Boyds, explores the latest trends in US drug development and initiatives at the FDA and discusses their potential impact on drug development in 2024.
Navigating the complexities of rare disease drug development
![](https://boydconsultants.com/wp-content/uploads/2024/02/Website-news-cover-image-size-82-1.png)
In this article, Dr Eric Hardter, Associate Director of Regulatory Affairs at Boyds, discusses the investigational phase of the rare disease drug development process with a focus on US regulatory requirements.
The FDA Pre-IND Meeting – A Best Practice for Mitigating Early Regulatory Risk
![FDA Pre-IND meeting](https://boydconsultants.com/wp-content/uploads/2024/02/Website-news-cover-image-size-74.png)
In this blog, Dr Eric Hardter, Associate Director of Regulatory Affairs, discusses the critical importance of proper planning and early engagement with FDA for Investigational New Drug (IND) applications.
Navigating the regulatory landscape in oncology drug development
![oncology drug development](https://boydconsultants.com/wp-content/uploads/2024/01/Website-news-cover-image-size-72.png)
In this blog, Boyds’ Dr Katherine Bowen, Senior Director of Regulatory Affairs, and Dr Julie Warner, Vice President of Regulatory Affairs, explore the ever-evolving world of oncology drug development and the regulatory landscape in the US and EU.